Search for: "Lisa Ouellette" Results 81 - 100 of 146
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
21 Dec 2016, 4:18 am by Edith Roberts
” At Written Description, Lisa Ouellette surveys the seven intellectual property cases on the Supreme Court’s docket so far this term, remarking that the crowded IP docket confirms “the conventional wisdom” that the eight-member court “would shy away from politically sensitive cases that could lead to 4-4 splits, focusing instead on areas such as intellectual property in which cases tend to be unanimous. [read post]
29 Feb 2016, 7:10 am by The CGCP Team
  Their panel is entitled Judicial Reform, Including Establishment of Specialized IP Courts and Use of Case Law as Precedent; Judicial Explanation on Patent Law, featuring both speakers, WANG Chuang, Deputy Chief Judge of the IPR Tribunal, Supreme People’s Court of China, and SLS professor Lisa Larrimore Ouellette. [read post]
20 Jun 2016, 3:12 am by Amy Howe
” In another post at Legal Aggregate, Lisa Ouellette weighs in on the Court’s recent ruling in Halo Electronics v. [read post]
9 Aug 2018, 10:24 am by Rebecca Tushnet
As usual, I have to skip a lot of interesting presentations and I try to attend things I haven’t seen, no matter how good the ones I have already seen/read drafts of are.Session 1: Trademarks Jason George (and Lisa Larrimore Ouellette), Trademarks as Innovation IncentivesNot saying that the goal is/should be innovation. [read post]
12 May 2020, 7:49 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceThe antiviral drug remdesivir, developed by California-based biopharmaceutical company Gilead Sciences in collaboration with government scientists, has emerged as the new standard of care for COVID-19 patients. [read post]
12 May 2020, 7:49 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceThe antiviral drug remdesivir, developed by California-based biopharmaceutical company Gilead Sciences in collaboration with government scientists, has emerged as the new standard of care for COVID-19 patients. [read post]
2 Feb 2016, 12:24 pm by Lawrence B. Ebert
Student editors are unlikely to have strong familiarity with the technical concepts that form the subject of many law review articles in the area of intellectual property.The previous post on IPBiz had allluded to some of the problems in the textSeparately, some commentary from Lisa Larrimore Ouellette related to Lemley's Myth of the Solo Inventor, and "review" of law review articles:Lemley isn't making any claims about the scope of the patents these inventors… [read post]
3 Feb 2016, 11:40 am by Lawrence B. Ebert
And in the few circumstances where that is not true – where inventions truly are "singletons" – it is often because of an accident or error in the experiment rather than a conscious effort to invent.In spite of Lemley's explicit reference to "bamboo" in the abstract of his law review, Lisa Larrimore Ouellette wrote:Lemley isn't making any claims about the scope of the patents these inventors received, so whether "bamboo" appears… [read post]
31 May 2016, 4:44 pm by Camilla Alexandra Hrdy
As a result, patents may strongly "pull" inventors towards innovations that are likely to be highly profitable–regardless of whether these innovations have the highest possible social value, or any lasting social value at all.Due to the limitations Sachs identifies, several scholars, such as Lisa Ouellette, Kapcynski, Peter Lee, myself, Jim Bessen, and others at various "Beyond IP" conferences, have explored alternatives to exclusive rights,… [read post]
7 Aug 2015, 1:39 pm by Rebecca Tushnet
   Lisa Larrimore Ouellette, Stanford Law School Collegiality/welcoming is a big benefit of coming here. [read post]
14 Mar 2014, 12:46 pm by Guest Blogger
  As Lisa Larrimore Ouellette observes in her blog post for this conference, and co-authored paper with Daniel Hemel, delayed and speculative rewards under an ex post incentive regime can deter creative investment. [read post]
23 Jan 2017, 11:56 pm by Lawrence B. Ebert
Further to the IPBiz post The theme of independent invention, and whether the same thing was invented , which in part discussed Mark Lemley'sMyth of the Sole Inventor, a previous post on IPBiz had noted:Separately, some commentary from Lisa Larrimore Ouellette related to Lemley's Myth of the Sole Inventor, and "review" of law review articles:Lemley isn't making any claims about the scope of the patents these inventors received, so whether… [read post]
5 Mar 2020, 5:15 am by Léon Dijkman
Daniel Hemel and Lisa Larrimore Ouellette suggested that the government award a "large cash prize for any firm that develops a successful coronavirus vaccine". [read post]
17 Mar 2020, 10:29 am by Camilla Hrdy
But I initially encountered it when the authors presented an early draft at the 2012 Yale Law School Information Society Project's "Innovation Beyond IP Conference," conceived and brought together by Amy Kapczynski and Written Description's Lisa Ouellette. [read post]
17 Mar 2020, 10:29 am by Camilla Hrdy
But I initially encountered it when the authors presented an early draft at the 2012 Yale Law School Information Society Project's "Innovation Beyond IP Conference," conceived and brought together by Amy Kapczynski and Written Description's Lisa Ouellette. [read post]
24 Jun 2016, 9:05 am by Amy Howe
At Legal Aggregate, Lisa Ouellette analyzes the Court’s recent decision in Cuozzo Speed Technologies v. [read post]
20 Jan 2015, 12:12 pm by Michael Risch
Luckily, Lisa Larrimore Ouellette, who runs Written Description, heard about my bloglessness and invited me to join her blog. [read post]
6 Oct 2014, 5:36 am by Amy Howe
  At Written Description, Lisa Larrimore Ouellette previews next week’s argument in Teva Pharmaceuticals v. [read post]